Redeye returns with a more in-depth take on the Q2 report.
Redeye notes a soft Q2 on both sales and EBIT, and we expect a negative share price reaction today of around -5%.
Redeye leaves its preview of RaySearch’s Q2 2025 results due on Friday, August 8.
Redeye returns with a more in-depth take on the Q1 report.
Redeye notes an exceptionally strong Q1 with record sales.
Redeye shares its preview for RaySearch’s Q1 2025 report, due May 9.
Redeye initiates coverage of RaySearch, a software company offering treatment planning systems for radiotherapy clinics.